Brooklyn ImmunoTherapeutics and Novellus have been doing quite a bit of business together lately, including a licensing agreement and co-locating at a research and development center. Now, a potential acquisition can be added to the growing list.
As a result of the termination, argenx will regain worldwide rights to cusatuzumab, its anti-CD70 antibody, from Cilag FmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The new vaccination, dubbed VAXELIS, is indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.
The clinical trial, which will be conducted by Xilio, will assess XTX101’s safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.
AbbVie’s Allergan Aesthetics’ most well-known brands right now include BOTOX and CoolSculpting, among others. However, with the company’s latest acquisition, another one might slide its way to the top.
See the companies featured in our 2021 maps, explore the territories that are thriving in the life sciences industry, research leading employers and search for relevant jobs on BioSpace.
As the world continues to navigate through the coronavirus pandemic, many biopharma companies are surging ahead with job creations. Check out these companies that have made recent job expansion announcements.
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
Novartis, Novartis Hellas and Alcon Inc. have agreed to pay a total of more than $346 million to settle bribery charges under the Foreign Corrupt Practices Act (FCPA), which is a U.S. anti-bribery law.
